Another extensive study based on the mouse model of Trem2–/– and wildtype mice in 3-methylcholanthrene-induced sarcoma, colorectal cancer and mammary tumor showed that anti-PD-1 immunotherapy is more effective in Trem2 deficient mice as compared to wild type mice. The gene discussed is TREM2; the disease is sarcoma.